INCHEON, South Korea, March 13, 2015 -- Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results